Stratec (ETR:SBS) has been given a €102.00 ($120.00) target price by equities researchers at Warburg Research in a research note issued to investors on Tuesday, Borsen Zeitung reports. The brokerage currently has a “sell” rating on the stock. Warburg Research’s price target would indicate a potential downside of 7.61% from the company’s current price.
Other equities research analysts also recently issued reports about the stock. Berenberg Bank set a €130.00 ($152.94) price target on shares of Stratec and gave the company a “neutral” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft set a €151.00 ($177.65) price target on shares of Stratec and gave the company a “buy” rating in a research report on Thursday, April 1st. Finally, Kepler Capital Markets set a €129.00 ($151.76) price target on shares of Stratec and gave the company a “buy” rating in a research report on Wednesday, December 9th.
Shares of ETR:SBS opened at €110.40 ($129.88) on Tuesday. The company has a debt-to-equity ratio of 63.93, a quick ratio of 2.48 and a current ratio of 4.38. Stratec has a one year low of €74.50 ($87.65) and a one year high of €145.00 ($170.59). The business’s 50-day simple moving average is €116.70 and its 200 day simple moving average is €121.26. The company has a market cap of $1.34 billion and a P/E ratio of 55.98.
STRATEC SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates in three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers.
See Also: Cost of Capital Explained
Receive News & Ratings for Stratec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec and related companies with MarketBeat.com's FREE daily email newsletter.